 |
CpG oligodeoxynucleotides (or CpG ODNs)
CpG motifs in unmethylated DNA molecules possess immunomodulatory properties with therapeutic potential. |
 .....Read More. |
| CpG oligodeoxynucleotides (or CpG ODNs) | ||||||
| Catalog Number | Product Description | Product Type | Size | |||
| ATODN1-1 | AT ODN-Non-CpG AT rich ODN. TLR9 agonist.-Antigen grade | ODNs/DNAs | 100 ug | |||
| ATODN2-1 | AT ODN-Non-CpG AT rich ODN. TLR9 agonist.-Antigen grade | ODNs/DNAs | 100 ug | |||
| ATODN3-1 | AT ODN-Non-CpG AT rich ODN. TLR9 agonist.-Antigen grade | ODNs/DNAs | 100 ug | |||
| AV-1015-10 | Adjuphos® aluminum phosphate (Th2) Vaccine adjuvant, FDA Approved | ODNs/DNAs | 10 ml | |||
| AV-1015-50 | Adjuphos® aluminum phosphate (Th2) Vaccine adjuvant, FDA Approved | ODNs/DNAs | 50 ml | |||
| AV-1020-100 | Calcium phosphate vaccine adjuvant | Adjuvant | 100 ml | |||
| AV-2000-PK-1 | PLGA Combo Trial Pak-1 (Contains 100 mg each of AV-2010-1; AV-2020-1 and AV-2030-1) | Adjuvant | 1 pk | |||
| AV-2010-1 | PLGA poly(lactic-co-glycolic) acid); synthetic; (50% lactic and 50% glycolic acid, ~30-60 Kda) | ODNs/DNAs | 0.1 g | |||
| AV-2020-1 | PLGA poly(lactic-co-glycolic) acid); synthetic; (65% lactic and 35% glycolic acid, ~ 40-75 Kda) | Adjuvant | 1 g | |||
| AV-2030-1 | PLGA poly(lactic-co-glycolic) acid); synthetic; (75% lactic and 25% glycolic acid, ~ 65-105 Kda) | ODNs/DNAs | 1 g | |||
| AV-2040-1 | PLGA poly(lactic-co-glycolic) acid); synthetic (75% lactic and 25% glycolic acid; Ester capped, , MW 75-115 Kda) | ODNs/DNAs | 1 g | |||
| AV-2050-1 | Poly(lactide-co-glycolide) star, glucose core, hydroxyl terminated vaccine adjuvant | ODNs/DNAs | 0.1 g | |||
| AV-2060-1 | Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) | Adjuvant | 1 g | |||
| AV-2070-1 | Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) | ODNs/DNAs | 0.1 g | |||
| AV-3000-PK-1 | Classical Adjuvant Combo Pak-1 (contains 10 ml each CFA (#AV-3010-10); IFA (AV-3015-10), and Squalene (#AV-3020-10) | Adjuvant | 1 pk | |||
| AV-3010-10 | Complete Freund?s Adjuvant (CFA);vaccine adjuvant | Adjuvant | 10 ml | |||
| AV-3010-100 | Complete Freund?s Adjuvant (CFA);vaccine adjuvant | Adjuvant | 10x10 ml | |||
| AV-3015-10 | Incomplete Freund?s Adjuvant (IFA);vaccine adjuvant | Adjuvant | 10 ml | |||
| AV-3015-100 | Incomplete Freund?s Adjuvant (IFA);vaccine adjuvant | Adjuvant | 10x10 ml | |||
| AV-3020-10 | Squalene (oil-in-water nano emulsion);vaccine adjuvant | Adjuvant | 10 ml | |||
| AV-4000-PK-1 | Saponins vaccine adjuvant Combo Pak-1 (contains 1mg of QS21,100 mg of Vet-SAP and 1 g of Saponin). | Adjuvant | 1 pk | |||
| AV-4010-1 | QS-21 (Quillaja saponaria), Vaccine adjuvant, (EU GMP grade) >95% | Adjuvant | 1 mg | |||
| AV-4010-5 | QS-21 (Quillaja saponaria), Vaccine adjuvant, (EU GMP grade) >95% | Adjuvant | 5 mg | |||
| AV-4020-100 | Vet-SAP Vaccine adjuvant, (EU GMP grade) >95%; | Adjuvant | 100 mg | |||
| AV-4020-1000 | Vet-SAP Vaccine adjuvant, (EU GMP grade) >95%; | Adjuvant | 1 g | |||
| AV-4030-10 | Saponin (Quillaja bark) pure, (sapogenin 25-35%) | Adjuvant | 10 g | |||
| AV-4031-10 | Saponin (Quillaja bark) pure, (sapogenin =10%) | Adjuvant | 10 g | |||
| AV-5000-PK-1 | Oil Adjuvant Combo Pak-1 (Contains 10 ml Peanut Oil (#AV-5010-10); Mineral oil (#AV-5020-10) and 1 g Mannide monooleate (#AV-5030-1) | Adjuvant | 1 pk | |||
| AV-5010-50 | Peanut Oil vaccine adjuvant | Adjuvant | 50 ml | |||
| AV-5020-50 | Mineral Oil vaccine adjuvant | Adjuvant | 50 ml | |||
| AV-5030-5 | Mannide monooleate vaccine adjuvant | Adjuvant | 5 g | |||
| AV-6010-100 | HS15 Kolliphore vaccine adjuvant | Adjuvant | 100 g | |||
| AV-7000-PK-1 | LPS/MPLA/MDP vaccine adjuvant Combo Pak-1 (contains 1 mg each of LPS (#AV-7015-1), MPLA-SM (#AV-7025-1) and MDP (#AV-7035-1); | Adjuvant | 1 pk | |||
| AV-7010-50 | Recombinant flagellin FlicC vaccine adjuvant (TLR5 agonist); vaccine adjuvant | Adjuvant | 50 ug | |||
| AV-7015-1 | Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant | Adjuvant | 1 mg | |||
| AV-7015-10 | Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant | Adjuvant | 10 mg | |||
| AV-7016-1 | Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant, ultrapure, TLR4 tested | Adjuvant | 1 mg | |||
| AV-7016-5 | Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant, ultrapure, TLR4 tested | Adjuvant | 5 mg | |||
| AV-7020-1 | Lipopolysaccharides (LPS) (Salmonella typhimurium) vaccine adjuvant | Adjuvant | 1 mg | |||
| AV-7020-10 | Lipopolysaccharides (LPS) (Salmonella typhimurium) vaccine adjuvant | Adjuvant | 10 mg | |||
| AV-7025-1 | Monophosphoryl lipid A (MPLA)-SM (S. enterica Minnesota, R595),vaccine adjuvant | Adjuvant | 1 mg | |||
| AV-7025-5 | Monophosphoryl lipid A (MPLA)-SM (S. enterica Minnesota, 595),vaccine adjuvant | Adjuvant | 5 mg | |||
| AV-7030-1 | Monophosphoryl lipid A (MPLA) (Synthetic, TLR4/Th1) vaccine adjuvant | Adjuvant | 1 mg | |||
| AV-7030-5 | Monophosphoryl lipid A (MPLA) (Synthetic, TLR4/Th1) vaccine adjuvant | Adjuvant | 5 mg | |||
| AV-7035-1 | MDP, muramyldipetide (Ac-muramyl-Ala-D-Glu-amide) Synthetic; vaccine adjuvant | Adjuvant | 1 mg | |||
| AV-7035-5 | MDP, muramyldipetide (Ac-muramyl-Ala-D-Glu-amide) Synthetic; vaccine adjuvant | Adjuvant | 5 mg | |||
| AV-7040-1 | Diphosphoryl Lipid A (E. coli K12 D31m4) | Adjuvant | 1 mg | |||
| AV-7040-5 | Diphosphoryl Lipid A (E. coli K12 D31m4) | Adjuvant | 5 mg | |||
| AV-7045-25 | Peptidoglycan (S. aureus); vaccine adjuvant | Adjuvant | 25 mg | |||
| AV-7045-5 | Peptidoglycan (S. aureus); vaccine adjuvant | Adjuvant | 5 mg | |||
| AV-8000-PK-1 | Synthetic Adjuvant Combo Pak-1 (contains 1 mg of Gardiquimod (#AV-8010), Imiquimod (#AV-8015) and 1 mg R848 (#AV-8020-1) | Adjuvant | 1 pk | |||
| AV-8010-25 | Gardiquimod (TLR7 agonist/Imidazoquinoline), antigen grade | Adjuvant | 25 mg | |||
| AV-8010-5 | Gardiquimod (TLR7 agonist/Imidazoquinoline), antigen grade | Adjuvant | 5 mg | |||
| AV-8015-25 | Imiquimod (TLR7 agonist/Imidazoquinoline), antigen grade | Adjuvant | 25 mg | |||
| AV-8015-5 | Imiquimod (TLR7 agonist/Imidazoquinoline), antigen grade | Adjuvant | 5 mg | |||
| AV-8020-1 | Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade | Adjuvant | 1 mg | |||
| AV-8020-5 | Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade | Adjuvant | 5 mg | |||
| AV-9000-PK-2 | Synthetic Adjuvant Combo Pak-2 (contains 1 mg of Pam2csk4 (#AV-9020-1), 1 mg of Pam3csk4 (#AV-9025-1) and 1 mg of Poly(I:C) (#AV-9030) | Adjuvant | 1 pk | |||
| AV-9010-1 | RWJ 21757 Synthetic vaccine adjuvant | Adjuvant | 1 mg | |||
| AV-9010-5 | RWJ 21757 Synthetic vaccine adjuvant | Adjuvant | 5 mg | |||
| AV-9015-2 | TDB (Trehalose-6,6-dibehenate) Synthetic vaccine adjuvant | Adjuvant | 2 mg | |||
| AV-9020-1 | Pam2CSK4 vaccine adjuvant, unlabeled | Adjuvant | 1 mg | |||
| AV-9020-B | Pam2CSK4 vaccine adjuvant; Biotin conjugate | Adjuvant | 1 mg | |||
| AV-9020-B-100 | Pam2CSK4 vaccine adjuvant; Biotin conjugate | Adjuvant | 100 ug | |||
| AV-9025-1 | Pam3CSK4 vaccine adjuvant, unlabeled | Adjuvant | 1 mg | |||
| AV-9025-B | Pam3CSK4 vaccine adjuvant; Biotin labelled | Adjuvant | 100 ug | |||
| AV-9025-F | Pam3CSK4 vaccine adjuvant; FITC labelled | Adjuvant | 100 ug | |||
| AV-9030-10 | Poly(I:C) (Polyinosinic-Polycytidylic) Synthetic | Adjuvant | 10 mg | |||
| AV-9030-50 | Poly(I:C) (Polyinosinic-Polycytidylic) Synthetic | Adjuvant | 50 mg | |||
| AV-9105-25 | Tetanus Toxoid from C. tetani purified, vaccine grade | ODNs/DNAs | 25 ug | |||
| AV-9110-10 | Recombinant purified tetani toxin Light-chain (Non toxic) | Adjuvant | 10 ug | |||
| AV-9115-10 | Recombinant (P. fluorescens) purified tetani toxin C-terminal fragment (~52 Kda, >95% pure, low endotoxin) | Adjuvant | 10 ug | |||
| AV-9120-500 | Purified Diphtheria Toxoid protein antigen grade | Adjuvant | 500 ug | |||
| AV-9125-100 | Purified CRM197 (Diphtheria Toxin mutant) protein vaccine grade | Adjuvant | 100 ug | |||
| AV-9135-1000 | Purified Cholera Toxin protein; vaccine grade | Adjuvant | 1 mg | |||
| AV-9135-500 | Purified Cholera Toxin protein; vaccine grade | Adjuvant | 500 ug | |||
| AV-9145-10 | Purified Pasteurella multocida Toxin (146 kda), vaccine grade | ODNs/DNAs | 10 ug | |||
| AV-9150-10 | Purified Exotoxin A from P. aeruginosa, vaccine grade | Adjuvant | 100 ug | |||
| AV-9200-PK-1 | Bacterial endotoxins Combo Pak-1 (contains 25 ug Tetanus toxoid (#AV-9105-25); 100 ug Diphtheria Toxin (#AV-9120-25);Diphtheria Toxin and 500 ug cholera toxin (#AV-9135-25;) | ODNs/DNAs | 1 pk | |||
| AV-9305-10 | Keyhole Limpet Hemocyanin (Megathura Crenulata) | ODNs/DNAs | 10 mg | |||
| AV-9305-100 | Keyhole Limpet Hemocyanin (Megathura Crenulata) | ODNs/DNAs | 100 mg | |||
| AV-9310-1000 | Chicken egg ovalbumin (Gal d 2) protein (ELISA, antigen, allergy grade) | ODNs/DNAs | 1 g | |||
| AV-9315-1 | Ovalbumin peptide OVA (Gal d 2, 257-264) class I MHC molecule | ODNs/DNAs | 1 mg | |||
| AV-9315-10 | Ovalbumin peptide OVA (Gal d 2, 257-264) class I MHC molecule | ODNs/DNAs | 10 mg | |||
| AV-9320-1 | Ovalbumin peptide OVA (Gal d 2, 323-339) MHC class II peptide | ODNs/DNAs | 1 mg | |||
| AV-9320-10 | Ovalbumin peptide OVA (Gal d 2, 323-339) MHC class II peptide | ODNs/DNAs | 10 mg | |||
| CIODN-1 | Core-iODN-Class I-Murine TLR9 Antagonist, antigen grade | ODNs/DNAs | 100 ug | |||
| EXA15-N-100 | Purified Exotoxin A from P. aeruginosa | Rec. Protein | 10 ug | |||
| GODN-1 | G-ODN Murine TLR9 antagonist-Antigen grade | ODNs/DNAs | 200 ug | |||
| ODN-NT-1 | Neutral ODN control ODN without agonistic nor antagonistic activity antigen grade | ODNs/DNAs | 100 ug | |||
| ODN-PK-1 | Mouse TLR9-agonist kit; contains 100 ug of ODN1585-1; ODN1826-1, ODN2395-1, and negative controls ODN1585-1NC; ODN1826-1-1NC, ODN2395-1NC | ODNs/DNAs | 1 pk | |||
| ODN-PK-2 | Human TLR9-agonist kit; contains 100 ug of ODN2006-1; ODN2216-1; ODN2395-1; and negative controls ODN2006-1NC; ODN2216-1NC; ODN2395-1NC | ODNs/DNAs | 1 pk | |||
| ODN-PK-3 | TLR9-antagonist kit; contains 100 ug of ODN2088-1; ODN4084-F; ODNINH-1; ODNINH-18; ONDTT-1. | ODNs/DNAs | 1 pk | |||
| ODN-PK-4 | TLR9-A&C class agonist kit, Contains 100 ug of ODN1585-1; ODN2216-1; ODN2336-1;ODN 2395 and ODN M362; ODNDSL03 | ODNs/DNAs | 1 pk | |||
| ODN-PK-5 | TLR9-B class agonist kit, Contains 100 ug of - ODN1668-1; ODN1826;and ODN2006 - ODN BW006 - B class, human/mouse - ODN 2007 - B-class, bovine/porcine - ODN D-SL01 | ODNs/DNAs | 1 pk | |||
| ODN006-1 | ODNBW006 Type B CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3' end | ODNs/DNAs | 1 mg | |||
| ODN1585-1 | ODN 1585-Type A murine TLR9 agonist-Antigen grade | ODNs/DNAs | 1 mg | |||
| ODN1585-1NC | ODN 1585-Type A murine TLR9 agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN1585-5 | ODN 1585-ype A murine TLR9 agonist-Antigen grade | ODNs/DNAs | 5 mg | |||
| ODN1585-5NC | ODN 1585-Type A murine TLR9 agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN1585-B | ODN 1585-Type A murine TLR9 agonist Biotin Conjugate, antigen grade | ODNs/DNAs | Custom | |||
| ODN1585-F | ODN 1585-Type A murine TLR9 agonist FITC conjugate Antigen grade | ODNs/DNAs | Custom | |||
| ODN1668-1 | ODN 1668-Type B murine TLR9 Agonist-Antigen grade | ODNs/DNAs | 1 mg | |||
| ODN1668-1NC | ODN 1668- Type B murine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN1668-5 | ODN 1668-Type B murine TLR9 Agonist-Antigen grade | ODNs/DNAs | 5 mg | |||
| ODN1668-5NC | ODN 1668- Type B murine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN1668-B | ODN 1668 -Type B murine TLR9 Agonist biotin conjugate- Antigen grade | ODNs/DNAs | Custom | |||
| ODN1668-F | ODN 1668-Type B murine TLR9 Agonist FITC conjugate- Antigen grade | ODNs/DNAs | Custom | |||
| ODN1826-1 | ODN 1826- Type B murine TLR9 Agonist-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN1826-1NC | ODN 1826- Type B murine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN1826-5 | ODN 1826- Type B murine TLR9 Agonist-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN1826-5NC | ODN 1826- Type B murine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN1826-B | ODN 1826- Type B murine TLR9 Agonist Biotin conjugate, antigen grade | ODNs/DNAs | Custom | |||
| ODN1826-F | ODN 1826- Type B murine TLR9 Agonist FITC conjugate, antigen grade | ODNs/DNAs | Custom | |||
| ODN2006-1 | ODN 2006 -Type B-human TLR9 agonist-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2006-1NC | ODN 2006- Type B human TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2006-5 | ODN 2006 -Type B-human TLR9 agonist-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2006-5NC | ODN 2006- Type B human TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2006-B | ODN 2006 -Type B-human TLR9 agonist Biotin conjugate-antigen grade | ODNs/DNAs | 50 ug | |||
| ODN2006-F | ODN 2006 -Type B-human TLR9 agonist FITC conjugate-antigen grade | ODNs/DNAs | Custom | |||
| ODN2007-1 | ODN 2007-Type B bovine/porcineTLR9 agonist-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2007-1NC | ODN 2007- Type B bovine/porcine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2007-200 | ODN 2007-Type B bovine/porcineTLR9 agonist-antigen grade, 200 ug | ODNs/DNAs | 200 ug | |||
| ODN2007-5 | ODN 2007-Type B bovine/porcineTLR9 agonist-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2007-5NC | ODN 2007- Type B bovine/porcine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2041-1 | ODN 2041-Non-CpG ODN. Invitro control for rabbit cells. Antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2088-1 | ODN 2088- Murine Class I TLR9 Antagonist.-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2088-1NC | ODN 2088- Class I-Murine TLR9 Antagonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2088-5 | ODN 2088- Murine Class I TLR9 Antagonist.-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2088-5NC | ODN 2088- Class I-Murine TLR9 Antagonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2216-1 | ODN 2216-Type A human TLR9 Agonist.-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2216-1NC | ODN 2216- Type A human TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2216-200 | ODN 2216-Type A human TLR9 Agonist.-antigen grade, 200ug | ODNs/DNAs | 200 ug | |||
| ODN2216-5 | ODN 2216-Type A human TLR9 Agonist.-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2216-5NC | ODN 2216- Type A human TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2216-B | ODN 2216-Type A human TLR9 Agonist Biotin conjugate-antigen grade | ODNs/DNAs | Custom | |||
| ODN2216-F | ODN 2216-Type A human TLR9 Agonist FITC conjugate-antigen grade | ODNs/DNAs | Custom | |||
| ODN2336-1 | ODN 2336- Type A human specific TLR 9 agonist-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2336-1NC | ODN 2336- Type A human specific TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2336-5 | ODN 2336- Type A human specific TLR 9 agonist-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2336-5NC | ODN 2336- Type A human specific TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2336-F | ODN 2336 -Type A human specific TLR 9 agonist-antigen grade | ODNs/DNAs | Custom | |||
| ODN2395-1 | ODN 2395-Type C human/murine TLR9 agonist-antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2395-1NC | ODN 2395- Type C human/ murine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODN2395-5 | ODN 2395-Type C human/murine TLR9 agonist-antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2395-5NC | ODN 2395- Type C human/ murine TLR9 Agonist (Negative Control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODN2395-F | ODN 2395-Type C human/murine TLR9 agonist FITC conjugate-antigen grade | ODNs/DNAs | 50 ug | |||
| ODN4084F-1 | ODN 4084-Type B Inhibitory TLR9 Antagonist.-antigen grade | ODNs/DNAs | 200 ug | |||
| ODN4084F-5 | ODN 4084-Type B Inhibitory TLR9 Antagonist.-antigen grade | ODNs/DNAs | 5 mg | |||
| ODNDSL01-1 | Type C CpG ODN and a TLR9 agonist, antigen grade | ODNs/DNAs | 200 µg | |||
| ODNDSL03-1 | Type B CpG ODN and a TLR9 agonist, antigen grade | ODNs/DNAs | 200 µg | |||
| ODNIHN1-1 | ODN INH-1-Class R (restricted) inhibitory ODN-TLR 9 Antagonist-antigen grade | ODNs/DNAs | 200 ug | |||
| ODNINH18-1 | ODN INH-18 class R (?restricted?) inhibitory ODN-TLR9 antagonist antigen grade | ODNs/DNAs | 200 µg | |||
| ODNINH47-1 | ODN INH-47-Class R (restricted) inhibitory ODN TLR9 Antagonist-Palindromic variant of ODN INH-1-antigen grade | ODNs/DNAs | 200 ug | |||
| ODNM362-1 | ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade | ODNs/DNAs | 1 mg | |||
| ODNM362-1NC | ODN M362-Type C human/murine TLR9 agonist (negative control), antigen grade | ODNs/DNAs | 1 mg | |||
| ODNM362-5 | ODN M362-Type C human/murine TLR9 agonist-antigen grade-antigen grade | ODNs/DNAs | 5 mg | |||
| ODNM362-5NC | ODN M362-Type C human/murine TLR9 agonist (negative control), antigen grade | ODNs/DNAs | 5 mg | |||
| ODNM362-B | ODN M362-Type C human/murine TLR9 agonist Biotin conjugate-antigen grade | ODNs/DNAs | Custom | |||
| ODNM362-F | ODN M362-Type C human/murine TLR9 agonist FITC conjugate-antigen grade | ODNs/DNAs | Custom | |||
| ODNTT-1 | ODN TTAGGG-Class G Human-TLR 9 Antagonist, antigen grade | ODNs/DNAs | 1 mg | |||
| ODNTT-1NC | ODN TTAGGG-Class G Human-TLR 9 Antagonist, antigen grade | ODNs/DNAs | 1 mg | |||
| PDNA15-N-100 | Baceterial Plasmid dsDNA, >95% pure | ODNs/DNAs | 100 ug | |||
| R848-1 | Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade | ODNs/DNAs | 1 mg | |||
| R848-5 | Resiquimod (Imidazoquinoline compound)-TLR7/8 agonist, antigen grade | ODNs/DNAs | 5 mg | |||
| RP-343 | Recombinant (E.Coli) Anti-Tetanus Toxoid scFv IgG | Antibodies | 10 ug | |||
| SIODN-1 | Inhibitory iODN- class I/II hybrid, may also affect TLR7 and TLR8 signaling. | ODNs/DNAs | 100 ug | |||
| AV-1000-PK-1 | Alum Gel Combo, Trial Pak-1 (Contains 10 ml each of Alhydrogel, Adjuphos, and Calcium Phosphate gels) | 1 pk | ||||
| AV-1010-100 | Alhydrogel 2%, Vaccine adjuvant, FDA Approved | 100 ml | ||||
| AV-1010-50 | Alhydrogel 2%, Vaccine adjuvant, FDA Approved | 50 ml | ||||
